Head-to-head comparison
| Property | AOD-9604 | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Reclassification Pending | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~1-2 hours | ~7 days |
| Mol. Weight | 1,815.08 Da | 4,113.58 Da |
| Side Effects | Injection site redness, Headache, Mild nausea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Evidence quality: Semaglutide has extensive Phase III clinical trials (STEP program, 10,000+ participants); AOD-9604 has limited clinical data and failed to demonstrate significant weight loss in its Phase IIb obesity trial.
- Mechanism: Semaglutide activates GLP-1 receptors to reduce appetite and slow gastric emptying; AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that is proposed to stimulate lipolysis without the anabolic or diabetogenic effects of full GH.
- FDA status: Semaglutide is FDA-approved for both diabetes and obesity; AOD-9604 is not FDA-approved and received GRAS (Generally Recognized as Safe) status only as a food ingredient, not as a weight loss drug.
- Efficacy: Semaglutide produces 15–17% body weight loss in trials; AOD-9604 did not demonstrate statistically significant weight loss over placebo in its Phase IIb trial.
- Administration: Semaglutide is injected weekly; AOD-9604 is typically injected daily subcutaneously in off-label protocols.
- Appetite effects: Semaglutide significantly reduces appetite; AOD-9604 does not have notable appetite-suppressing effects.
- Cost and availability: Semaglutide is a prescription medication available through pharmacies; AOD-9604 is available as a research peptide with variable quality from unregulated suppliers.
The verdict
Semaglutide is the dramatically stronger option by every clinical metric: superior trial data, FDA approval, proven efficacy, and established safety profile. AOD-9604 failed to demonstrate significant weight loss in clinical trials and lacks FDA approval as a therapeutic. While AOD-9604 remains available as a research compound and is discussed in biohacking communities, the evidence gap between these two compounds is substantial. This comparison is less about choosing between equals and more about understanding the difference between a proven therapeutic and an investigational compound.
Frequently asked questions
No. Semaglutide has demonstrated 15–17% body weight loss in large Phase III trials. AOD-9604 failed to show statistically significant weight loss over placebo in its Phase IIb trial. The evidence gap is substantial.
AOD-9604 is popular in biohacking communities due to its origin as a growth hormone fragment, its theoretical lipolytic mechanism, and its availability from peptide suppliers. Its GRAS status is sometimes misinterpreted as FDA efficacy approval (it is not—GRAS applies to its safety as a food ingredient only).
AOD-9604 is not FDA-approved as a therapeutic for any indication. It received GRAS (Generally Recognized as Safe) status as a food ingredient in 2015, which is a safety classification, not an efficacy or therapeutic approval.
They work through different mechanisms (GH fragment vs GLP-1 receptor), so there is no direct pharmacological conflict. However, no clinical studies have evaluated this combination, and given AOD-9604's failure to demonstrate independent efficacy, the rationale for combination is unclear.
AOD-9604 was specifically designed to retain the lipolytic effects of growth hormone without the diabetogenic effects—it should not raise blood sugar. Semaglutide improves blood sugar control as a core mechanism (it is FDA-approved for type 2 diabetes). In this respect, semaglutide has a favorable metabolic profile.